Skip to main content
Afsaneh Barzi, MD, Oncology, Duarte, CA, Keck Hospital of USC

AfsanehBarziMDPhD

Oncology Duarte, CA

Gastrointestinal Cancer

Associate Professor of Medical Oncology, City of Hope Comprehensive Cancer Center

Dr. Barzi is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Barzi's full profile

Already have an account?

Education & Training

  • Cleveland Clinic Foundation
    Cleveland Clinic FoundationFellowship, Hematology and Medical Oncology, 2008 - 2011
  • University of Texas Medical Branch Hospitals
    University of Texas Medical Branch HospitalsResidency, Internal Medicine, 2001 - 2004
  • Tehran University of Medical Sciences School of Medicine
    Tehran University of Medical Sciences School of MedicineClass of 1996

Certifications & Licensure

  • CA State Medical License
    CA State Medical License 2011 - 2025
  • NV State Medical License
    NV State Medical License 2023 - 2025
  • AK State Medical License
    AK State Medical License 2022 - 2024
  • RI State Medical License
    RI State Medical License 2021 - 2024
  • OH State Medical License
    OH State Medical License 2008 - 2011
  • TX State Medical License
    TX State Medical License 2005 - 2008
  • American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

  • Top Doctors:LA Area Castle Connolly, 2013
  • Top Doctors:Southern California Castle Connolly, 2012

Clinical Trials

Publications & Presentations

PubMed

Lectures

  • Patient-reported outcomes (PRO) before and after colorectal cancer (CRC) by race in a national survey. 
    ASCO Gastrointestinal Cancers Symposium - San Francisco, CA - 1/25/2020
  • Total cost of care for patients (pts) with stage II colon cancer (CC-II): A SEER-Medicare analysis. 
    2019 ASCO Annual Meeting - 6/1/2019
  • Potential Role of Polymorphisms in the Transporter Genes ENT1 and MATE1/OCT2 in Predicting TAS-102 Efficacy and Toxicity in Patients with Refractory Metastatic Colorec... 
    2019 ASCO Annual Meeting - 6/1/2019

Press Mentions

  • Cardiff Oncology to Present New Data from Lead Clinical Program in KRAS-Mutated Metastatic Colorectal Cancer on September 8, 2021
    Cardiff Oncology to Present New Data from Lead Clinical Program in KRAS-Mutated Metastatic Colorectal Cancer on September 8, 2021August 25th, 2021
  • Trovagene : Announces Acceptance of Phase 1b/2 KRAS-Mutated Metastatic Colorectal Cancer Trial Abstract for Presentation at the 2020 ASCO Annual Meeting
    Trovagene : Announces Acceptance of Phase 1b/2 KRAS-Mutated Metastatic Colorectal Cancer Trial Abstract for Presentation at the 2020 ASCO Annual MeetingJune 16th, 2020
  • Onvansertib Show Early Signals of Safety and Efficacy in KRAS-Mutated mCRC
    Onvansertib Show Early Signals of Safety and Efficacy in KRAS-Mutated mCRCOctober 23rd, 2019
  • Join now to see all

Professional Memberships

Hospital Affiliations